Skip to content

Press Releases

Nov 13, 2020
NEXLETOL® (bempedoic acid) Tablets Highlighted at AHA 2020 with Presentations of Analyses Demonstrating Significant Low-Density Lipoprotein Cholesterol (LDL-C) Lowering vs. Placebo in Phase 3 Study Subgroups
- Significant mean reduction of 26.5% in LDL-C with bempedoic acid vs. placebo in pooled analysis of people who cannot tolerate statins 1 - - Analysis by sex showed bempedoic acid significantly lowered LDL-C at week 12 in males and females * vs. placebo 2 - ANN ARBOR, Mich., Nov.
Nov 12, 2020
Esperion Announces Pricing of Offering of $250.0 Million of Convertible Senior Subordinated Notes
ANN ARBOR, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the pricing of $250.0 million aggregate principal amount of 4.00% Convertible Senior Subordinated Notes due 2025 (the “notes”) in a private offering (the “offering”) to qualified institutional buyers
Nov 10, 2020
Esperion Announces Private Offering of $200.0 Million of Convertible Senior Subordinated Notes
ANN ARBOR, Mich., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of Convertible Senior Subordinated Notes due 2025 (the “notes”) in a private offering (the
Nov 06, 2020
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on November 4, 2020, the Compensation Committee of Esperion’s Board of Directors granted 33,663 restricted stock units (RSUs) to 24 new colleagues under Esperion’s 2017 Inducement Equity Incentive
Nov 02, 2020
ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update
– Quarter-over-quarter Script Growth Exceeded 500 Percent for NEXLETOL ® (bempedoic acid) and NEXLIZET ® (bempedoic acid and ezetimibe) tablets – – U.S. Product Revenue Increased Five-fold During the Third Quarter – – ESPERION Partner Daiichi Sankyo Europe Launches NILEMDO™ (bempedoic acid) and
Oct 27, 2020
Esperion to Participate in Three Upcoming Virtual Investor Conferences
ANN ARBOR, Mich., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in three upcoming virtual conferences during the month of November. Event:   Credit Suisse 29 th Annual Virtual Healthcare Conference Date:   November 9,
Oct 19, 2020
Esperion to Report Third Quarter 2020 Financial Results November 2, 2020
ANN ARBOR, Mich., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report third quarter 2020 financial results after the close of the U.S. financial markets on Monday, November 2, 2020. Following the release, company management will host a webcast and conference
Oct 07, 2020
NEXLETOL® (bempedoic acid) Tablets Highlighted in EAS 2020 Presentation of Analysis Demonstrating Significant Cholesterol Lowering in People with Familial Hypercholesterolemia
- NEXLETOL® exhibited a 22% mean reduction in LDL-C levels in patients with Heterozygous Familial Hypercholesterolemia at week-12 - ANN ARBOR, Mich., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced results of pooled data from two of the company’s Phase 3 trials were
Sep 28, 2020
Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedoic acid) Tablets and Increase Awareness of Bad Cholesterol
ANN ARBOR, Mich., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the launch of “Break the Cycle with NEXLETOL”, a national direct-to-consumer (DTC) campaign aimed at broadening awareness of NEXLETOL® (bempedoic acid) Tablets and the never-ending patient cycle of diet,
Sep 02, 2020
Esperion to Participate in Two Upcoming Virtual Investor Conferences
ANN ARBOR, Mich., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the month of September. Event:  Citi 15 th Annual Biopharma Conference Date:  September 9, 2020 Format: 1:1